Abstract
Most patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have exhausted their treatment options and are deemed palliative. C......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
